# OnCo record click-activated-prodrugs (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/click-activated-prodrugs/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "click-activated-prodrugs" ;
  schema:name "Click-activated prodrugs (bioorthogonal drug activation in the body)"@en ;
  schema:alternateName "click chemistry prodrug activation"@en, "bioorthogonal prodrug activation"@en, "click-activated protodrugs"@en, "CAPAC"@en, "Click Activated Protodrugs Against Cancer"@en, "click-to-release"@en, "in vivo click chemistry"@en, "tetrazine ligation"@en ;
  schema:description "Two ingredients are given separately: one is placed at or guided to the tumour, the other is an inactive form of a cancer drug sent through the blood. Where they meet, a fast chemical reaction releases the active drug. One early trial in people showed the chemistry works in the body but did not shrink more tumours than the ordinary drug."@en ;
  schema:url <https://onco.cc/technologies/click-activated-prodrugs/> ;
  schema:dateModified "2026-11-16"^^xsd:date ;
  schema:citation <https://www.nobelprize.org/prizes/chemistry/2022/press-release/>, <https://doi.org/10.1158/1078-0432.CCR-24-2539>, <https://doi.org/10.1101/2025.06.02.25328445>, <https://doi.org/10.1039/d0sc06099b>, <https://www.shasqi.com/our-platform>, <https://clinicaltrials.gov/study/NCT04106492>, <https://www.tagworkspharma.com/>, <https://clinicaltrials.gov/study/NCT06959706> ;
  onco:status "phase-2" ;
  onco:tag "frontier" ;
  onco:sections <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/masked-adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/sq3370/> ;
  onco:companies <https://onco.cc/companies/shasqi/>, <https://onco.cc/companies/tagworks-pharmaceuticals/> ;
  onco:terms <https://onco.cc/terms/prodrug/>, <https://onco.cc/terms/therapeutic-index/>, <https://onco.cc/terms/payload/>, <https://onco.cc/terms/mmae/> ;
  onco:trials <https://onco.cc/trials/nct04106492/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/>, <https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/>, <https://onco.cc/key-papers/paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021/>, <https://onco.cc/key-papers/paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023/>, <https://onco.cc/key-papers/paper-mejia-oneto-local-hydrogel-systemic-prodrug-sarcoma-acs-cent-sci-2016/> .
